Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 7/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14991648 | 0.83 | TSHR (0.39) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL15143953 | 0.83 | MAPK1 (0.38) | TSHRCYP3A4MAPK1TDP1HTT | |
| SCHEMBL24730488 | 0.79 | PGR (0.41) | TSHRCYP3A4MAPK1TDP1HTT | |
| SCHEMBL16579383 | 0.78 | TSHR (0.44) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL30017641 | 0.78 | TSHR (0.44) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL16579355 | 0.77 | CYP3A4 (0.50) | SLC6A2HTR2ASLC6A4HRH1HTR2B | |
| SCHEMBL8389745 | 0.75 | HSD17B10 (0.48) | TSHRCYP3A4MAPK1TDP1HTT | |
| SCHEMBL29960430 | 0.75 | DDR1 (0.36) | TSHRCYP3A4MAPK1TDP1HTT | |
| SCHEMBL31193921 | 0.74 | TMPRSS4 (0.51) | TSHRCYP3A4MAPK1TDP1HTT | |
| SCHEMBL16579369 | 0.74 | TSHR (0.58) | SLC6A2HTR2ASLC6A4HRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719019-B1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-01-19 | — | — | EP | disclosed |
| EP-3719019-B1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-01-19 | — | — | EP | disclosed |
| EP-3204383-B1 | SPIRODIAMINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-3204383-B1 | SPIRODIAMINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-3719019-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719019-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-10-07 | — | — | EP | disclosed |
| EP-3004089-B1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2020-05-06 | — | — | EP | disclosed |
| EP-3004089-B1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2020-05-06 | — | — | EP | disclosed |
| EP-3004077-B1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-3004077-B1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | disclosed |
| WO-2016055394-A1 | SPIRODIAMINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| US-20160075686-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160075688-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160075687-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160075686-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160075688-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160075687-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| WO-2014191336-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014191340-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014191338-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075687-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | DRD4, QDPR, DRD3 | SLC6A2 3565/4885HTR2A 1046/4885SLC6A4 2467/4885 |
| US-20160075688-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | DRD4, QDPR, DRD3 | SLC6A2 3565/4885HTR2A 1046/4885SLC6A4 2467/4885 |
| US-20160075686-A1 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS | DRD4, DRD3, QDPR | SLC6A2 3628/4885HTR2A 1215/4885SLC6A4 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.